ライフサイエンスコーパス: allotransplant

1 recurrence and will not be offered a repeat allotransplant.

2 ow and its environment in a composite tissue allotransplant.

3 major histocompatibility complex mismatched allotransplants.

4 rejection of minor antigen disparate cardiac allotransplants.

5 and tapered corticosteroids, comparable with allotransplants.

6 n the elimination of malignant disease after allotransplants.

7 used myeloablative conditioning regimens for allotransplants.

8 (-) mice that spontaneously accepted a heart allotransplant and displayed donor-specific tolerance al

9 Immediately before the islet allotransplant and for 6 additional days, primates were

10 Upon tamoxifen-induced mutp53 ablation, allotransplanted and autochthonous tumours curb their gr

11 inal organs with multiple vascular composite allotransplants and tissues.

12 Rats received corneal allotransplants and were killed during acute rejection.

13 Seventy-six hemiface allotransplants, between ACI (RT1) donors and Lewis (RT1

14 resulted in 100% survival of mice receiving allotransplants challenged with an otherwise invariably

15 As with recipients of other allotransplants, CTA recipients can experience rejection

16 As with recipients of other allotransplants, CTA recipients can experience rejection

17 donor-specific tolerance to composite tissue allotransplants (CTAs).

18 At postoperative day 7, allotransplants developed moderate rejection as determin

19 Allotransplanted dogs that developed AR (n=8) and CR (n=

20 CNA staining in lung cultures from rejecting allotransplanted dogs was significantly greater than tha

21 g the potential for better outcomes in islet allotransplant for type 1 diabetes mellitus with refinem

22 al rates of insulin independence after islet allotransplant for type 1 diabetes, long-term islet func

23 We analyzed data from 396 recipients of allotransplants for DLBCL receiving myeloablative (MAC;

24 isolate human pancreatic islets intended for allotransplants generates a product that is hampered by

25 bserved after USPIO injection into rats with allotransplanted hearts.

26 n cold University of Wisconsin solution, and allotransplanted into recipient dogs for either 4 hr (gr

27 (2) proliferation is increased in rejecting allotransplanted lungs, (3) endothelin-A receptors media

28 lin 3 were reduced in bronchi from rejecting allotransplanted lungs.

29 rade of rejection was 2.74+/-0.17 (n= 19) in allotransplanted lungs; evidence of infection was presen

30 We've established a nonhuman primate islet allotransplant model to address questions such as whethe

31 In a preclinical, nonhuman primate islet allotransplant model, the authors evaluated a novel immu

32 r rapid and stable tolerance induction in an allotransplant model.

33 aftment/tolerance in exceptionally stringent allotransplant models by (1) limiting the early expansio

34 receptor blockade in mouse cardiac and islet allotransplant models has led to long-term engraftment a

35 for rapid and stable tolerance induction in allotransplant models.

36 r resulted in prolonged islet survival in an allotransplant mouse model.

37 The failure of pancreatic islet allotransplants observed in almost all clinical attempts

38 possibility of performing a complex vascular allotransplant of all neck organs including skin.

39 f transplanted organs from the same species (allotransplant) or different species (xenotransplant).

40 One hundred thirty-two consecutive renal allotransplant patients, who underwent transplantation o

41 particles at postoperative day 6, a group of allotransplanted rats was treated with cyclosporin A (3

42 by using data from 1827 HLA-matched sibling allotransplant recipients reported to the International

43 ecretion was observed in either the auto- or allotransplant recipients, whereas healthy control subje

44 d beta-cell phenotype in 2 intraportal islet allotransplant recipients.

45 raction of bronchi from autotransplanted and allotransplanted rejecting lungs.

46 But how the innate immune cells respond to allotransplants remains poorly defined.

47 valuable in many clinical situations such as allotransplants, some autoimmunities, as well as with so

48 turation of APCs, and significantly improves allotransplant survival.

49 Treated hemiface/mandible/tongue allotransplants survived up to 385 days, without signs o

50 Sixty-seven percent of remitters received an allotransplant that delivered superior survival compared

51 ional successful multiple vascular composite allotransplants, thoracic, and abdominal organ recoverie

52 Allotransplants to apolipoprotein-E-deficient recipients

53 his shows that failure of orthotopic corneal allotransplants to elicit a CD4+ T-cell direct allorespo

54 bone marrow compartment in composite tissue allotransplants to potentially induce immune tolerance.

55 Most islet allotransplant tolerance induction protocols have been t

56 lity and function of Treg cells for inducing allotransplant tolerance or treating autoimmune conditio

57 esus monkeys undergoing MHC-mismatched islet allotransplants treated with belatacept and the mTOR inh

58 The markedly reduced toxicity of allotransplants using nonmyeloablative regimens (mini-al

59 lerance to kidney and vascularized composite allotransplants (VCA).

60 To test this, corneal allotransplants were performed in either inflamed (high-

61 Orthotopic corneal allotransplants were performed in low-risk (nonvasculari

62 p I received composite musculocutaneous flap allotransplants (WF-->Lew) with immunosuppression allowi